Can Tumor Mutations Cause Resistance to Cellular Immunotherapy?
Chimeric antigen receptor T-cell therapy, or CAR T, has been a huge breakthrough for certain types of blood cancers. First approved in 2017, the therapy uses a patient’s own immune cells, which are removed and sent to a lab where they are genetically engineered, adding a receptor to help them better seek out cancer cells. Once infused back into the patient, the CAR T cells can easily find and attack the tumors.